Moderna, Inc.
MRNA Details
Moderna, Inc. (NASDAQ: MRNA) is a commercial-stage biotechnology company created in 2010. As of early 2021, Moderna had 24 mRNA development programmes, with 13 of those in clinical trials. Infectious disease and oncology are among the therapeutic areas covered by the programmes.
The Company announced on February 3, 2022, that it would report the fourth quarter and full-year 2021 financial results on February 24, 2022.
Latest News:
- New Collaboration: On February 16, 2022, MRNA and Laboratorios Farmacéuticos Rovi, S.A. has established a long-term partnership to expand ROVI's compounding, aseptic filling, inspection, labelling, and packaging capacities in Madrid.
- Expansion in Asia Pacific Region: On February 15, 2022, Moderna, Inc. announced the addition of four new subsidiaries in Malaysia, Taiwan, Singapore, and Hong Kong to its commercial network in Asia. This expansion comes as the Company ramps up the production and distribution of its COVID-19 vaccine and future mRNA vaccines and therapeutics.
- Agreement with the Govt of Columbia: On February 8, 2022, Moderna, Inc. announced a new supply agreement with the Colombian government for 10.8 million doses of Moderna's COVID-19 vaccine. These doses are in addition to the 10 million doses that Colombia will receive in 2021.
Financial Highlights: Q3FY21 (ended on September 30, 2021)
(Source: Company Filing)
- Solid topline performance: The company has reported a total revenue of US5D bn in Q3FY21, a growth from USD 157m in the same quarter of the previous financial year. Rise in sales is mainly attributed to the commercial sales of its Covid-19 vaccine (Spikevax) as well as grant revenue to a smaller extent.
- Posted positive net income: Net income in Q3FY21 stood at USD 3.3bn compared to a net loss of USD 233m in the prior-year period. Strong bottom line performance is mainly driven by significant reduction in cost of sales as % to revenue.
- Improved liquidity: Company’s liquidity profile strengthened significantly to USD 15.3 bn as of September 30, 2021, compared to USD 5.2 bn reported as of December 31, 2020.
Key Risks:
- Delay in regulatory approvals: Positive efficacy and safety data from ongoing clinical studies of our COVID-19 vaccine, as well as the FDA's EUA, may not be indicative of the results of the clinical trials, which is one of several factors that could delay from receiving full regulatory approval for the vaccine.
- Government policy risk: One or more government actions or interventions may limit the Company's capacity to produce a viable vaccine and deliver it to clients, likely during a global health catastrophe like COVID-19.
Valuation Methodology: EV/Sales Multiple based Relative Valuation
Analysis by Kalkine Group
Stock Recommendation:
The company reported decent performance in the Q3FY21 driven by sales of 208 million doses of the Covid-19 vaccine. Further the company expects to realize product sales between USD15 and USD18bn for FY2021 and plans to supply 700-800 million 100µg doses of its Covid-19 vaccine this fiscal year. However, Therefore, given its robust financials, new arrangements and expansions, current valuation, and risk associated, we recommend a "Buy" rating on the stock at the current market price of USD 147.95, February 16, 2022, at 01:51 PM ET.
1-Year Technical Price Chart (as on February 16, 2022, at 01:50 PM ET). Source: REFINITIV, Analysis by Kalkine Group
Technical Summary Analysis
Technical Indicators Defined: -
Support: A level where-in the stock prices tend to find support if they are falling, and downtrend may take a pause backed by demand or buying interest.
Resistance: A level where-in the stock prices tend to find resistance when they are rising, and uptrend may take a pause due to profit booking or selling interest.
Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices.
Note 1: The reference data in this report has been partly sourced from REFINITIV.
Note 2: Investment decision should be made depending on the investors' appetite on upside potential, risks, holding duration, and any previous holdings. Investors can consider exiting from the stock if the Target Price mentioned as per the valuation has been achieved and subject to the factors discussed above.
Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.
Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.
You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.
The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.
Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information.
On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.